Hormonal and metabolic effects of chlorpropamide, glibenclamide and placebo in a cross-over study in diabetics not controlled by diet alone [PDF]
, 1981 Peter H. Sönksen +3 more
openalex +1 more source
Molecular Oncology, EarlyView.In this explorative biomarker analysis, we assessed serial sampling of circulating tumor cells (CTCs) with CellSearch in two randomized trials testing immune checkpoint inhibitors (ICIs) in metastatic breast cancer. Our data demonstrate a prognostic potential of CTCs, most apparent 4 weeks into ICI therapy.
Nikolai Kragøe Andresen +13 more
wiley +1 more source
Is my study cross-sectional or longitudinal?
Medisur, 2023 The studies’ classification as cross-sectional or longitudinal constitutes one of the methodological aspects that are declared in the research projects corresponding to the specialty’s completion works.
Luis Alberto Corona Martínez +1 more
doaj
Double-Blind Cross-Over Placebo Controlled Study of Flunarizine in Patients With Therapy Resistant Epilepsy [PDF]
, 1989 Elout Starreveld +4 more
openalex +1 more source
Cell‐free and extracellular vesicle microRNAs with clinical utility for solid tumors
Molecular Oncology, EarlyView.Cell‐free microRNAs (cfmiRs) are small‐RNA circulating molecules detectable in almost all body biofluids. Innovative technologies have improved the application of cfmiRs to oncology, with a focus on clinical needs for different solid tumors, but with emphasis on diagnosis, prognosis, cancer recurrence, as well as treatment monitoring.
Yoshinori Hayashi +6 more
wiley +1 more source
SMALL SAMPLE SIZE IN 2X2 CROSS OVER DESIGNS: CONDITIONS OF DETERMINATION
Journal of Research in Medical Sciences, 2001 Introduction. Determination of small sample size in some clinical trials is a matter of importance. In cross-over studies which are one types of clinical trials, the matter is more significant.
B SOLEYMANI +3 more
doaj
Molecular Oncology, EarlyView.The authors applied joint/mixed models that predict mortality of trifluridine/tipiracil‐treated metastatic colorectal cancer patients based on circulating tumor DNA (ctDNA) trajectories. Patients at high risk of death could be spared aggressive therapy with the prospect of a higher quality of life in their remaining lifetime, whereas patients with a ...
Matthias Unseld +7 more
wiley +1 more source
Peripheral blood proteome biomarkers distinguish immunosuppressive features of cancer progression
Molecular Oncology, EarlyView.Immune status significantly influences cancer progression. This study used plasma proteomics to analyze benign 67NR and malignant 4T1 breast tumor models at early and late tumor stages. Immune‐related proteins–osteopontin (Spp1), lactotransferrin (Ltf), calreticulin (Calr) and peroxiredoxin 2 (Prdx2)–were associated with systemic myeloid‐derived ...
Yeon Ji Park +6 more
wiley +1 more source
Clomipramine vs desipramine vs placebo in the treatment of diabetic neuropathy symptoms. A double‐blind cross‐over study. [PDF]
, 1990 Søren H. Sindrup +5 more
openalex +1 more source
Adverse prognosis gene expression patterns in metastatic castration‐resistant prostate cancer
Molecular Oncology, EarlyView.We aggregated a cohort of 1012 mCRPC tissue samples from 769 patients and investigated the association of gene expression‐based pathways with clinical outcomes. Loss of AR signaling, high proliferation, and a glycolytic phenotype were independently prognostic for poor outcomes, and an adverse transcriptional feature score incorporating these pathways ...
Marina N. Sharifi +26 more
wiley +1 more source